Identification of relevant biomarkers for lung cancer to improve prediction
2015
University of Michigan, Ann Arbor, USA
Knowledge of the molecular alterations and immune microenvironment present in lung cancer have allowed patients' stratification according to their outcome and the identification of new targets for therapy development. Still, novel biomarkers are needed to predict patients prognosis and therapy response. MAP3K3 is an enzyme involved in both the immune response and tumor progression. In this study, the researchers studied in vitro the roles of MAP3K3 in cell proliferation, migration, invasion and effects on cell cycle following MAP3K3 knockdown using short interference RNA in lung cancer cell lines. Further, the researchers analyzed the MAP3K3 protein/mRNA expression in primary lung cancers and its association with clinical-pathological characteristics including patient survival. Results indicate that MAP3K3 overexpression correlates with an active immune response in the tumor environment in parallel with improved patient survival. MAP3K3 may potentially not only serve as a diagnostic/prognostic marker for patients with lung cancer but also provide an indicator for future investigations into immunomodulatory therapies for lung cancer.
MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer
Guoan Chen
Added on: 07-28-2021
[1] https://www.nature.com/articles/srep11471[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
